company background image
SCP logo

Scancell Holdings DB:SCP Stock Report

Last Price

€0.14

Market Cap

€156.6m

7D

-16.3%

1Y

9.4%

Updated

24 Nov, 2024

Data

Company Financials +

SCP Stock Overview

A clinical stage biopharmaceutical company, engages in the discovery and development of novel immunotherapies and vaccines for the treatment of cancer and infectious disease. More details

SCP fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health1/6
Dividends0/6

Scancell Holdings plc Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Scancell Holdings
Historical stock prices
Current Share PriceUK£0.14
52 Week HighUK£0.23
52 Week LowUK£0.071
Beta0.45
11 Month Change-11.47%
3 Month Change-14.72%
1 Year Change9.45%
33 Year Change-43.95%
5 Year Change172.55%
Change since IPO-64.63%

Recent News & Updates

Recent updates

Shareholder Returns

SCPDE BiotechsDE Market
7D-16.3%-0.7%-0.02%
1Y9.4%-17.2%8.2%

Return vs Industry: SCP exceeded the German Biotechs industry which returned -17.2% over the past year.

Return vs Market: SCP exceeded the German Market which returned 8.2% over the past year.

Price Volatility

Is SCP's price volatile compared to industry and market?
SCP volatility
SCP Average Weekly Movement22.3%
Biotechs Industry Average Movement6.5%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.9%
10% least volatile stocks in DE Market2.3%

Stable Share Price: SCP's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: SCP's weekly volatility (22%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
199761Phil L'Huillierwww.scancell.co.uk

Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel immunotherapies and vaccines for the treatment of cancer and infectious disease. Its product candidates include SCIB1, an ImmunoBody cancer vaccine that is in Phase II for the treatment of metastatic melanoma; and SCIB2/iSCIB2 vaccine, which is under evaluation for the treatment of patients with solid tumors, including non-small cell lung cancer. It also develops Modi-1, a citrullinated peptides vaccine that is in phase I/II clinical trials for the treatment of solid tumors including triple negative breast, melanoma, ovarian, lung, and pancreatic cancers; and Modi-2, which targets homocitrullinated cancer antigens.

Scancell Holdings plc Fundamentals Summary

How do Scancell Holdings's earnings and revenue compare to its market cap?
SCP fundamental statistics
Market cap€156.60m
Earnings (TTM)-€7.05m
Revenue (TTM)n/a

0.0x

P/S Ratio

-22.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SCP income statement (TTM)
RevenueUK£0
Cost of RevenueUK£0
Gross ProfitUK£0
Other ExpensesUK£5.86m
Earnings-UK£5.86m

Last Reported Earnings

Apr 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.0063
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio-541.3%

How did SCP perform over the long term?

See historical performance and comparison